Trials for Respiratory Syncytial Virus (RSV) now using flu-iiQ™

There is currently strong global interest in Respiratory Syncytial Virus (RSV) and consequently several trials are now using the flu-iiQ™ as an outcome measure for the development and testing of new treatments and vaccines in this setting. The initial development and testing work on the flu-iiQ™ included ‘Influenza Like Illness’ (ILI) – for which it was found to work equally well as for influenza. The use of the flu-iiQ™ in RSV trials therefore makes good sense.